SPY305.55+1.23 0.40%
DIA255.27+0.98 0.39%
IXIC9,552.05+62.18 0.66%

Cantor Fitzgerald Maintains Overweight on Crinetics Pharmaceuticals, Raises Price Target to $38

Cantor Fitzgerald maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and raises the price target from $28 to $38.

Benzinga · 05/11/2020 15:38

Cantor Fitzgerald maintains Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Overweight and raises the price target from $28 to $38.